Clinical Trial Update: Metabolic Effects of Adjunctive Lumateperone Treatment in Clozapine-Treated Patients With Schizophrenia [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating metabolic effects of adjunctive lumateperone in clozapine-treated patients with schizophrenia is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizoaffective Disorder
• Schizophrenia

Drugs mentioned

• CLOZARIL (Clozapine)
• Caplyta (lumateperone) (lumateperone)

Snippet

Sponsor: University of Massachusetts, Worcester | Conditions: Schizophrenia, Schizo Affective Disorder | Phase 4 | Status: RECRUITING